SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

HDG & JL

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
concapk Member Profile
 
Followed By 0
Posts 80
Boards Moderated 0
Alias Born 04/17/13
160x600 placeholder
Amended Statement of Changes in Beneficial Ownership (4/a) "Edgar (US Regulatory)" - 12/4/2017 4:48:02 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/4/2017 9:04:12 AM
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular ... "GlobeNewswire Inc." - 11/14/2017 4:30:00 PM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Pat... "GlobeNewswire Inc." - 11/13/2017 4:30:00 PM
Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical ... "GlobeNewswire Inc." - 11/13/2017 6:00:00 AM
Amarin to Present at the Jefferies London Healthcare Conference "GlobeNewswire Inc." - 11/7/2017 6:00:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/1/2017 6:35:17 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/1/2017 6:31:37 AM
Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations "GlobeNewswire Inc." - 11/1/2017 5:30:00 AM
Amarin to Report Third Quarter 2017 Results and Host Conference Call on November 1, 2017 "GlobeNewswire Inc." - 10/25/2017 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/6/2017 7:23:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:26:27 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:26:02 PM
Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada "GlobeNewswire Inc." - 9/25/2017 6:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 9/22/2017 1:08:41 PM
Amarin to Present at Cantor Global Healthcare Conference "GlobeNewswire Inc." - 9/20/2017 4:30:00 PM
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer "GlobeNewswire Inc." - 9/13/2017 6:00:00 AM
Amarin to Present at Rodman & Renshaw’s Global Investment Conference "GlobeNewswire Inc." - 9/6/2017 6:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/30/2017 4:02:36 PM
Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Moni... "GlobeNewswire Inc." - 8/14/2017 6:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) "Edgar (US Regulatory)" - 8/2/2017 5:06:42 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/2/2017 6:38:43 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/2/2017 6:31:46 AM
Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations "GlobeNewswire Inc." - 8/2/2017 5:30:00 AM
Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017 "GlobeNewswire Inc." - 7/26/2017 4:30:00 PM
concapk   Thursday, 10/05/17 07:58:29 PM
Re: Biobillionair post# 115582
Post # of 118990 
HDG & JL

Please understand their are many ways to view situations. I for one agree with Bio that the FDA did point blank screw us back on Oct 13th.

Both of you look at it from a medical viewpoint which you are 100% correct. The FDA realized their mistake and found ways to circumvent the situation not to give AMARIN 35 million potential subscribers without positive results concerning trig lowering to lowering cvd events.

I look at it from a business viewpoint as does BIO that the FDA set up and agreed to an SPA with AMARIN. AMARIN was, an is a small company required to run a 7000 modified to an 8000 CVOT study costing approx. $250/300 million.
This study called REDUCE-IT would take approx. 4 years to complete and that cost would be mitigated by sales from ANCHOR approval. The FDA knew that they would be harming AMARIN by rescinding the SPA, "THEY DIDN'T CARE".

They could have modified the SPA 6 months prior to the ADCOM as Bio has stated. Hdg you said maybe AMARIN was informed and proceeded anyway, which could be true. I think the FDA hedged their situation through out the process knowing the power they haD (my opinion).

Now we are 4 years into the study near the end with double the number of shares from approx 170 to 340 million potentially issued. Those shares paid for REDUCE-IT hurting all original investors.

YES, this is now water under the bridge with results forthcoming. YES, we need to put this behind us and look to the bright future ahead. But as investors, we were hurt badly with many of us still under water so to say. PLEASE don't give the FDA any positive credence for what they did.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist